Albumin Market: Growth Opportunities Through 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Albumin Market Between 2026 And 2030?

The albumin market has experienced robust expansion in recent times. It is projected to expand from $7.16 billion in 2025 to $7.81 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.1%. This historical expansion was fueled by elements such as the constrained supply of plasma-derived albumin, the increasing prevalence of liver diseases and burns, its heightened application in diagnostic kits, an uptick in biopharmaceutical R&D activities, and its early integration into laboratory and research uses.

The albumin market is anticipated to experience robust expansion over the next few years. It is projected to achieve a value of $10.62 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.0%. This anticipated growth can be attributed to advancements in recombinant albumin technology, the increasing demand for personalized medicine, broader application of albumin in drug delivery systems, an upsurge in biopharmaceutical manufacturing, and escalating investment in therapeutic and cosmetic applications. Key developments expected during this period include a rising demand for human serum albumin in therapeutic contexts, the expanding utilization of albumin in drug formulations and vaccines, wider integration of recombinant albumin applications within biopharma, increased adoption of albumin in cell culture and diagnostic kits, and a strong focus on albumin-based research and personalized medicine.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/albumin-global-market-report

What Key Factors Are Shaping The Albumin Market Landscape?

The escalating occurrence of diabetes is projected to fuel the expansion of the albumin market in the future. Diabetes is a persistent metabolic condition marked by high blood glucose, which can eventually lead to kidney issues like diabetic nephropathy. A primary contributor to the increasing prevalence of diabetes is growing obesity rates, supported by significant epidemiological data that highlights a strong link between higher body mass index values and a considerably increased risk of diabetes. Albumin aids in patient care through assisting with kidney function monitoring and directing treatment strategies for individuals with diabetes. As an illustration, in April 2025, data from the International Diabetes Federation (IDF), a non-profit organization based in Belgium, indicated that diabetes impacted an estimated 589 million adults and 9.5 million people with type 1 diabetes in 2024, a figure that included 1.9 million children and adolescents. The overall number of individuals living with this condition is anticipated to reach 853 million by 2050. Consequently, the growing occurrence of diabetes is a key impetus for the expansion of the albumin market.

How Are Different Segments Classified In The Albumin Market Segment Analysis?

The albumin market covered in this report is segmented –

1) By Type: Human Serum Albumin, Bovine Serum Albumin, Recombinant Albumin

2) By Application: Therapeutics, Drug Formulation And Vaccines, Component Of Media, Other Applications

3) By End-User: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Research Institutes

Subsegments:

1) By Human Serum Albumin: Plasma-Derived Human Serum Albumin, Recombinant Human Serum Albumin, Human Serum Albumin For Therapeutic Use (In Liver Disease, Burns), Human Serum Albumin For Drug Delivery And Research Applications

2) By Bovine Serum Albumin: Bovine Serum Albumin For Laboratory Use (In Cell Culture), Bovine Serum Albumin For Diagnostic Kits, Bovine Serum Albumin As A Stabilizer In Vaccines And Biopharmaceuticals

3) By Recombinant Albumin: Recombinant Human Albumin For Therapeutic Applications, Recombinant Albumin For Biopharmaceutical Formulation, Recombinant Albumin For Cosmetic And Personal Care Applications, Recombinant Albumin For Research And Diagnostic Applications

What Market Trends Are Affecting The Albumin Market?

Companies operating in the albumin market are prioritizing the development of advanced products, such as animal- and human-origin-free recombinant albumin, to better serve customers with enhanced capabilities. An animal- and human-origin-free recombinant albumin signifies an albumin type manufactured using a non-mammalian expression system, like yeast, thereby containing no components derived from animals or humans. For instance, in March 2023, Albumedix, a UK-based manufacturer of recombinant human albumin (rHA), formed a partnership with Heartseed Inc., a Japan-based clinical-stage biotech company, to launch Recombin. Recombin is a crucial excipient intended for use in the production of Heartseed’s investigational cell therapy, HS-001, as its initial first-in-human clinical trial commences. This collaboration marks a significant progression in the development of HS-001, which is anticipated to revolutionize the treatment landscape for various diseases. The incorporation of Recombin into the manufacturing process ensures the cell therapy’s optimal functionality and stability, further solidifying its potential for therapeutic triumph.

Who Are The Companies Driving Activity In The Albumin Market?

Major companies operating in the albumin market are Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, Baxter International Inc., CSL Limited, Grifols SA, Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Kedrion S.p.A., Biotest AG, Jiangxi Boya Bio-Pharmaceutical Co. Ltd., BPL (Bio Products Laboratory), Kamada Ltd., Proliant Biologicals, SeraCare Life Sciences Inc., HiMedia Laboratories, Albumedix Ltd., Medxbio Pte Ltd., Ventria Bioscience Inc., China Biologic Products Holdings Inc.

Get The Full Albumin Market Report:

https://www.thebusinessresearchcompany.com/report/albumin-global-market-report

Which Region Is The Leading Market For The Albumin Market?

North America was the largest region in the albumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the albumin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Albumin Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/albumin-global-market-report

Browse Through More Reports Similar to the Global Albumin Market 2026, By The Business Research Company

Catalogue Market Report 2026

https://www.thebusinessresearchcompany.com/report/catalogue-global-market-report

Albumin Excipient Market Report 2026

https://www.thebusinessresearchcompany.com/report/albumin-excipient-global-market-report

Music Recording Market Report 2026

https://www.thebusinessresearchcompany.com/report/music-recording-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795